eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | tuberous sclerosis |
| Symptom | C0004114|astrocytomas |
| Sentences | 28 |
| PubMedID- 20643042 | Objective: presentation of 8 patients with subependymal giant-cell astrocytomas (sgca) associated with tuberous sclerosis complex (tsc). |
| PubMedID- 23158521 | Everolimus for astrocytomas in tuberous sclerosis complex. |
| PubMedID- 24667738 | The burden of subependymal giant cell astrocytomas associated with tuberous sclerosis complex: results of a patient and caregiver survey. |
| PubMedID- 26381530 | Objective: to analyze the cumulative efficacy and safety of everolimus in treating subependymal giant cell astrocytomas (sega) associated with tuberous sclerosis complex (tsc) from an open-label phase ii study (nct00411619). |
| PubMedID- 23743818 | Recent studies support the use of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis and suggest it might represent a disease-modifying treatment for other aspects of tuberous sclerosis. |
| PubMedID- 21792104 | Mtor inhibitors in the treatment of subependymal giant-cell astrocytomas associated with tuberous sclerosis. |
| PubMedID- 26137524 | Everolimus has since also been fda-approved for neuroendocrine tumors of pancreatic origin (pnet), breast carcinoma, and subependymal giant cell astrocytomas (sega) associated with tuberous sclerosis. |
| PubMedID- 25493579 | The pathogenic activation of mtorc1 leads to the development of subependymal giant cell astrocytomas in patients with tuberous sclerosis complex. |
| PubMedID- 24276039 | Background: brain subependymal giant cell astrocytomas (segas) in patients with tuberous sclerosis have been reported to respond to everolimus. |
| PubMedID- 21047224 | Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. |
| PubMedID- 23582393 | Everolimus for astrocytomas in tuberous sclerosis - author's reply. |
| PubMedID- 25557360 | Background: the aim of the study was to investigate factors affecting response to everolimus, a mammalian-target-of-rapamycin (mtor) inhibitor, of subependymal giant cell astrocytomas (sega) in patients with tuberous sclerosis complex (tsc). |
| PubMedID- 23548133 | Down-regulation of mtor kinase by everolimus has been successfully used for the therapy of subependymal giant-cell astrocytomas in patients with tuberous sclerosis. |
| PubMedID- 24105488 | Subependymal giant cell astrocytomas in patients with tuberous sclerosis complex: considerations for surgical or pharmacotherapeutic intervention. |
| PubMedID- 23158522 | We assessed the efficacy and safety of everolimus in patients with subependymal giant cell astrocytomas associated with tuberous sclerosis complex. |
| PubMedID- 20133820 | Novel proteins regulated by mtor in subependymal giant cell astrocytomas of patients with tuberous sclerosis complex and new therapeutic implications. |
| PubMedID- 22647206 | Areas covered: the objective of this review is to discuss the history of key findings and innovative cancer research undertaken to successfully develop everolimus as an oncology therapy (afinitor) now approved for patients with advanced renal cell carcinoma (rcc) and for subependymal giant cell astrocytomas (segas) associated with tuberous sclerosis. |
| PubMedID- PMC3518234 | Down-regulation of mtor kinase by everolimus has been successfully used for the therapy of subependymal giant-cell astrocytomas in patients with tuberous sclerosis. |
| PubMedID- 23231513 | In patients with subependymal giant cell astrocytomas (segas) associated with tuberous sclerosis complex who are not candidates for surgery, single-agent everolimus has demonstrated the ability to significantly reduce sega volume with good tolerability. |
| PubMedID- 25227171 | Congenital subependymal giant cell astrocytomas in patients with tuberous sclerosis complex. |
| PubMedID- 20887114 | Rapamycin as an alternative to surgical treatment of subependymal giant cell astrocytomas in a patient with tuberous sclerosis complex. |
| PubMedID- 25002765 | The variety of astrocytomas commonly associated with tuberous sclerosis is the sega with incidences ranging from 6% to 16%. |
| PubMedID- 24056156 | Specific inhibitors of this pathway have been shown to reduce the volume of subependymal giant cell astrocytomas associated with tuberous sclerosis. |
| PubMedID- 21306252 | Everolimus and giant-cell astrocytomas in tuberous sclerosis. |
| PubMedID- 24192699 | Equally important avenues of molecular investigation might include inhibiting disease-causing pathways, such as the proposed use of rapamycin for subependymal giant cell astrocytomas in children with tuberous sclerosis;(83) upregulating affected proteins from homologous genes as in models of spinal muscular atrophy (84); or counteracting the downstream effects of a deficient protein, such as the proposed use of igf1 in children with duchenne’s dystrophy for review, please see liew, 2012 (85). |
| PubMedID- 21306253 | Everolimus and giant-cell astrocytomas in tuberous sclerosis. |
| PubMedID- 21297924 | From the bench to the bedside: everolimus for subependymal giant cell astrocytomas in tuberous sclerosis complex, optic nerve regeneration, targeted cytotoxins for gliomas. |
| PubMedID- 23582392 | Everolimus for astrocytomas in tuberous sclerosis. |
Page: 1